Pfizer Q2 Earnings Preview: Analysts Expect Modest Rebound in EPS and Revenue

Pfizer is set to report Q2 earnings on August 5th, with analysts projecting a modest performance rebound. The consensus EPS estimate is $0.57, a 5% decline YoY, and revenue is expected to reach $13.53 billion. The company's strong EPS beat streak faces a test, with investors eagerly awaiting the results.

Pfizer (NYSE:PFE) is set to report its second quarter earnings on Tuesday, August 5th, before the market opens, with analysts projecting a modest performance rebound. The consensus EPS estimate stands at $0.57, representing a 5.0% decline year-over-year, while revenue is expected to reach $13.53 billion, reflecting a 1.9% increase from the prior-year quarter [1].

The company's strong EPS beat streak faces a test, with investors eagerly awaiting the results. Pfizer has a history of exceeding EPS expectations, having done so in each of the past eight quarters. However, the company has only beaten revenue estimates half the time over the last two years, indicating potential top-line volatility [1].

Estimate trends have been broadly positive heading into the print: EPS estimates have seen 7 upward revisions and 3 downward over the past 90 days. Revenue estimates have been revised upward 8 times, with just 2 cuts during the same period [1].

Great Lakes Dredge & Dock (NASDAQ:GLDD) is also scheduled to announce Q2 earnings results on the same day, with the consensus EPS Estimate at $0.09 (-18.2% Y/Y) and the consensus Revenue Estimate at $177.7M (+4.5% Y/Y) [2].

References:
[1] https://seekingalpha.com/news/4477364-pfizers-strong-eps-beat-streak-faces-test-as-q2-earnings-loom
[2] https://seekingalpha.com/news/4477828-great-lakes-dredge-dock-q2-2025-earnings-preview